Memorandum of Cooperation between APBMEC and PhIRDA Signed in Sydney

On February 17, 2023, Sydney witnessed the successful signing of a memorandum of cooperation between APBMEC and PhIRDA. Dr Jun Hong Sun, Director of APBMEC, and Dr Ruilin Song, Executive President of PhIRDA, signed the memorandum of cooperation on behalf of their respective parties.

Asia-Pacific Bio-Med Exchange Centre INC (APBMEC) is a not-for-profit organization established in accordance with Australian law and regulations, aiming to promote biomedical and pharmaceutical exchange and cooperation within the Asia-Pacific region.
China Pharmaceutical Innovation and Research Development Association (PhIRDA) is a charity community group established in accordance with Chinese law, consisting of over 180 member organizations of pharmaceutical development, manufacturing and clinical research.
In order to promote international communication in Asia-Pacific health sector, meeting increasing clinical demands, addressing complex public health challenges, and increasing region and global clinical and medical level, APBMEC and PhIRDA have reached the following cooperation intentions:
International standard clinical trial workshops will be organized jointly by both parties; Clinical trial specialist seminars will be organized jointly by both parties; Both parties will jointly organize training in Pharmaceuticals and medical equipment registration regulations in Australia and China; APBMEC will organize for Australian research institutions and companies to participate in medical innovative investment conventions held by PhIRDA; Both parties will strive to promote communications between medical research personnel from both countries, especially in partnership in AI diagnosis application.

Both parties acknowledge that the Asia-Pacific region is the most economically active in the world. The implementation of regional partnership agreements brings vibrancy and strengthens the economy and trade relationship between ASEAN and China, Australia, New Zealand, Japan and Korea. Both parties look forward to the implementation of a plan of action to achieve above cooperation, contributing to intensive collaboration between Australia and China in healthcare and pharmaceutical sectors.
